Drugs / Optate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05799521 | Jun 2023 → Mar 2027 expected | COVID-19 | Indiana University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Optate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05799521 ↗ |
| Route | Inhaled | “investigational new inhaled medication called Optate” NCT05799521 ↗ |